New therapies – AIMSPRO
The Food and Drug Administration has at the end of February 2014 granted Orphan Drug designation to the therapy AIMSPRO, for systemic sclerosis. Widely known by the acronym FDA, the organisation has a wide-ranging effect on decisions made regarding drugs elsewhere in the world.
A double-blind, placebo-controlled Phase II clinical study evaluating the safety and tolerability of AIMSPRO given as a monotherapy to patients with Late Stage Established Diffuse Cutaneous Systemic Sclerosis (dSSc) is now wholly complete. The encouraging results from this study were published in Annals of Rheumatic Diseases.
The detailed announcement of the Orphan Drug designation is on Daval’s website :
http://www.davalinternational.com/news/news_17.html
news & events
6th World Scleroderma Patient Congress
FESCA is delighted to announce that the next World Scleroderma Patient Congress, which takes place in Prague from March 5-7, 2020, will be live-streamed.
Help us to keep smiling
We invite you from all over the world to post a picture/video with smiles on social medias like twitter, facebook, instagram etc with the hashtag #ScleroSmile
World Scleroderma Day 2019
PRESS RELEASE: European associations align in the battle against systemic sclerosis for World Scleroderma Day 2019